O'Neill joined FACIT in 2013 as vice president, business development, bringing cancer drug development expertise as well as an extensive business network in pharma and biotech.
As acting president for the last year, he has elevated the profile of the organization and enabled FACIT to continue to deliver critical commercialization financing to innovative start-ups in the growing Ontario market.
Through various business management roles at AstraZeneca, Ambit Biosciences, Kinomescan, and Fluorinov Pharma, O'Neill gained two decades of transaction, marketing, and seed stage investment experience.
He has also held operational roles, provided interim executive management to FACIT spin outs, serves on the board of Turnstone, and is a board observer for Hamilton-based Fusion Pharmaceuticals.
FACIT is the gateway to the cancer research pipeline in Ontario and functions as a bridge between the public and private sectors.
The company applies an entrepreneurial approach, along with strong business expertise and industry connections, to continuously identify and advance breakthroughs in science and technology to help move oncology innovations to real world opportunities that benefit investors, patients and the economy.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer